[Omalizumab and allergen immunotherapy: A clinical report and review of the literature].
Omalizumab et immunothérapie allergénique : cas clinique et revue de la littérature.
Allergen immunotherapy
Asthma
Asthme
Biotherapies
Biothérapies
Exacerbation
Immunothérapie allergénique
Omalizumab
Journal
Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
20
11
2017
accepted:
14
03
2018
pubmed:
7
11
2018
medline:
6
8
2019
entrez:
7
11
2018
Statut:
ppublish
Résumé
Several authors have proposed combined omalizumab and allergen immunotherapy (AIT) in patients suffering from severe allergic asthma to both increase disease control and decrease the severity through targeting the main allergen responsible for the respiratory symptoms. In a female pediatric patient suffering from severe asthma, followed-up at the University Hospital of Montpellier (France), we prescribed an AIT to Alternaria after obtaining symptom control with omalizumab. The patient showed an overall improvement in symptoms after AIT was administered and the disease remained controlled long after cessation of omalizumab. There are only a few publications evaluating the efficacy of the association of these two biotherapies in the management of severe allergic asthma. In addition there is, as yet, no common protocol for the administration of the two prescriptions. This approach to treatment would benefit from standardization in order to optimize the management of severe allergic asthma.
Identifiants
pubmed: 30396780
pii: S0761-8425(18)30335-8
doi: 10.1016/j.rmr.2018.03.006
pii:
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Omalizumab
2P471X1Z11
Types de publication
Case Reports
Journal Article
Review
Langues
fre
Pagination
191-196Informations de copyright
Copyright © 2018 SPLF. Published by Elsevier Masson SAS. All rights reserved.